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Human plasma kallikrein-kinin system proteins are related to inflammation through
bradykinin. In the proximity of its target cells, high molecular weight kininogen
(H-kininogen) is the substrate of plasma kallikrein, which releases bradykinin from
H-kininogen. Heparan sulfate proteoglycans (HSPGs) play a critical role in either
recruiting kinin precursors from the plasma, or in the assembly of kallikrein-kinin
system components on the cell surface. Furthermore, HSPGs mediate the endocytosis
and activation of H-kininogen and plasma prekallikrein. In the presence of HSPGs
(Chinese hamster ovary cell, CHO-K1, wild type cells) both heparin and heparan sulfate
strongly inhibit the H-kininogen interaction with the cell membrane. H-kininogen is
internalized in endosomal acidic vesicles in CHO-K1 but not in CHO-745 cells (mutant
cells deficient in glycosaminoglycan biosynthesis). The endocytosis process is lipid
raft-mediated and is dependent on caveolae. Both types of CHO cells do not internalize
bradykinin-free H-kininogen. At pH 7.35, bradykinin is released from H-kininogen on
the surface of CHO-745 cells only by serine proteases; however, in CHO-K1 cells
either serine or cysteine proteases are found to be involved. The CHO-K1 cell lysate
contains different kininogenases. Plasma prekallikrein endocytosis in CHO-K1 cells is
independent of H-kininogen, and also prekallikrein is not internalized by CHO-745
cells. Plasma prekallikrein cleavage/activation is independent of glycosaminoglycans
but plasma kallikrein formation is more specific on H-kininogen assembled on the cell
surface through glycosaminoglycans. In this mini-review, the importance of HSPGs in
the regulation of plasma kallikrein-kinin system proteins is shown.
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PLASMA KALLIKREIN-KININ SYSTEM
In humans, the physiological plasma kallikrein-kinin system (KKS) pathway is composed of high
molecular weight kininogen (H-kininogen), plasma pre (kallikrein) and bradykinin (BK). The KKS
pathway is very important for inflammatory processes, through BK activities that are mediated by
the constitutive G-protein-coupled receptor BK B2 (B2R) present in different cells (Regoli et al.,
1996; Schmaier, 2016).
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H-kininogen is a single polypeptide chain (120 kD),
characterized as a six domain multifunctional protein
playing antithrombotic, profibrinolytic, proinflammatory,
andantimicrobial roles, and is an inhibitor of cysteine proteases
and regulator of angiogenesis. After cleavage by plasma kallikrein
(KAL) at Lys362-Arg363 and Arg371-Ser372, the H-kininogen turns
BK-free H-kininogen into a two-chain protein composed of an
N-terminal heavy chain (containing three domains, D1–D3,
62 kD) and a C-terminal light chain (containing two domains,
D5–D6, 61 kD) bound to each other by a single disulfide bond
between Cys10-Cys596 (Colman and Schmaier, 1997; Lalmanach
et al., 2010).
The important peptide BK (Arg-Pro-Pro-Gly-Phe-Ser-Pro-
Phe-Arg) was first described by Mauricio Rocha e Silva and co-
workers (Rocha e Silva et al., 1949) as a substance that produces a
slow delayed contraction of the isolated guinea pig ileum after
incubation with either extracts of Bothrops jararaca venom or
trypsin with the globulin fraction of dog plasma. BK corresponds
to H-kininogen domain 4 (D4) and it reproduces many of the
characteristics of an inflammatory state, such as changes in local
blood pressure, edema, and pain, resulting in vasodilation and
increased microvessel permeability (Bhoola et al., 1992). The
release of pro-inflammatory and hyperalgesic mediators such as
neuropeptides, leukotrienes, and cytokines, and the activation
of sensory nerve terminals are the underlying causes of pro-
inflammatory and nociceptive pharmacological effects induced
by BK (Heitsch, 2003; Couture et al., 2014).
Plasma prekallikrein (PK) is the zymogen of KAL (EC
3.4.21.34), a serine protease synthesized predominantly in the
liver. Its mRNA codes for a single chain protein which, according
to the degree of glycosylation in the C-terminal portion, may
appear as a doublet (85 and 88 kD) independent of the
protein reduction. The classic activation of PK by factor XIIa
occurs through cleavage of the Arg371-Ile372 bond producing
KAL, containing an intact N-terminal heavy chain (53 kD)
and a C-terminal light chain (33–36 kD) linked via a single
disulfide bond between Cys364-Cys484. The protease domain is
in the light chain and contains the catalytic domain (His415,
Asp464, and Ser559) (Colman and Schmaier, 1997). PK and H-
kininogen circulate as bimolecular complexes and ∼75–80%
of PK circulates as bound at plasma equilibrium conditions
(Kaplan, 2014). The N-terminal heavy chain comprises four
apple domains (A1–A4) and the binding affinity sites on PK
for H-kininogen are A2>A4 ≈ A1>A3 (Renné et al., 1999).
Two forms of active KAL have been described: α-KAL which
presents both intact heavy and light chains, and β-KAL in
Abbreviations: BK, bradykinin; CHO, cell line from Chinese hamster ovary
cells; CK1, cytokeratin 1; CS, chondroitin sulfate; ECM, extracellular matrix;
ECV304, cell line from spontaneously transformed human umbilical vein
endothelial cells; gC1qR, globular domains of complement factor C1q receptor;
GAG, glycosaminoglycan; B2R, G-protein-coupled receptor bradykinin B2; H-
kininogen, high molecular weight kininogen; HNE, human neutrophil elastase;
HUVECs, human umbilical vein endothelial cells; HS, heparan sulfate; HSPGs,
heparan sulfate proteoglycans; KKS, plasma kallikrein-kinin system; KAL,
plasma kallikrein; MMP-9, metalloproteinase-9; PGs, proteoglycans; PK, plasma
prekallikrein; RAECs, rabbit aorta endothelial cell line; TIMP-1, tissue inhibitor of
metalloproteases-1.
which the heavy chain has undergone a single cleavage to
produce fragments of∼18,000 and 28,000 kD, linked by disulfide
bridges. Only one cleavage on the β-KAL heavy chain impairs
the efficiency of BK release; therefore, the heavy chain does
not seem to be necessary for non-specific cleavages of H-
kininogen by β-KAL (Motta et al., 1989; Page and Colman,
1991).
KAL plays a central role in a variety of proteolytic
systems, such as the intrinsic pathway of coagulation, the
KKS, the fibrinolysis pathway, the renin–angiotensin system,
and the complement pathways. Therefore, it can be considered
an important regulator in the pathogenesis of thrombosis,
inflammation, and blood pressure (Kolte and Shariat-Madar,
2016).
PLASMA KALLIKREIN-KININ SYSTEM AND
CELL SURFACE INTERACTION
In the intravascular compartment, the interaction and activation
of KKS on the cell surface of platelets, neutrophils, endothelial
cells, and macrophages have been described (Colman, 2006;
Schmaier and McCrae, 2007; Barbasz et al., 2008). The
membrane-binding proteins of H-kininogen or BK-free H-
kininogen on endothelial cells include the globular domains
of complement factor C1q receptor (gC1qR), urokinase
plasminogen activator receptor (uPAR) and cytokeratin 1
(CK1), in which the affinity measured using surface plasmon
resonance is gC1qR>CK1>soluble uPAR, indicating that gC1qR
is dominant for binding (Pixley et al., 2011).
Once assembled on the cell surface H-kininogen functions as
a putative receptor for PK; therefore, a lower affinity of PK can be
detected in the absence of added H-kininogen; the cell-associated
PK is rapidly converted to KAL in the presence of H-kininogen,
that is proteolyzed during the KAL formation producing BK,
and Motta et al. (1998) first describe the factor XII independent
pathway for contact factor activation on human umbilical vein
endothelial cells (HUVECs) that regulate BK production.
BK plays an important role in regulating angiogenesis through
upregulation of endogenous basic fibroblast growth factor
through the inductive G-protein-coupled receptor BK B1 or
viral fibroblast growth factor through the B2R, by regulation
of vascular permeability or stimulation of cell proliferation
through the B2R. The H-kininogen cleavage by KAL promotes
conformational changes in BK-free H-kininogen and exposure
of domain 5 (D5), which inhibits endothelial cell migration and
proliferation, both of which play a role in angiogenesis (Guo
and Colman, 2005). This potent anti-angiogenic activity occurs
through tight-binding to cell surface tropomyosin which also
induces endothelial cell apoptosis (McCrae et al., 2005). The
peptide sequence on H-kininogen D5, comprising the residues
His497–K520, is important for homing of both T and B cells
to lymph nodes, which is a powerful mechanism of coupling
inflammation to adaptive immunity (Ponda and Breslow, 2016).
PK is brought to the endothelial surface by H-kininogen
or BK-free H-kininogen since it binds to a peptide sequence
(Trp569-Lys595) on domain 6 (D6) (Vogel et al., 1990). The
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activation of the KKS on endothelial cells needs both H-
kininogen and zinc ions (Røjkjaer et al., 1998). Zinc ions mediate
both H-kininogen and BK-free H-kininogen binding with high
affinity to endothelial cells (Reddigari et al., 1993) and through
domain 5 (D5) both forms also bind with high affinity to heparin,
a negatively charged glycosaminoglycan (GAG; Björk et al.,
1989).
Heparin interacts with Lys and/or Arg residues within
proteins via electrostatic interaction and zinc facilitates binding
to heparin by binding to expose His residues and stabilizes
the non-covalent complex between heparin and both forms
of H-kininogen (Lin et al., 2000). H-kininogen D5 contains
two subdomains, a His-Gly-rich region (Lys420-Asp474) and a
His-Gly-Lys-rich region (His475-Lys502); H-kininogen exhibits a
higher affinity to heparin (lower KD) than BK-free H-kininogen
because the former loses a peptide sequence (Ser372-Arg419)
which corresponds to a third cleavage by KAL after BK release
from H-kininogen (Nakayasu and Nagasawa, 1979).
Several proteinases from two major classes, the serine and
cysteine proteases, cleave H-kininogen; nevertheless, they differ
in specificity and not all of them release BK or Lys-BK. Among
the serine proteases are KAL, tissue kallikrein, trypsin, factor
XIIa, factor XIa, plasmin and neutrophil elastase (Mauron
et al., 2000). At inflammatory sites, a combined action of
tryptase/neutrophil elastase or KAL/neutrophil elastase may
release kinins. Among cysteine proteases are calpains and
cathepsin L that release kinins fromH-kininogen at slightly acidic
pH, suggesting these enzymes as candidates for kinin production
in a pathophysiological environment (Lalmanach et al., 2010).
The findings of the current research group show that cathepsin
B has kininogenase activity at pH 6.3, which is improved
in the absence of divalent cations (Zn2+, Mg2+, and Ca2+),
however, at pH 7.35 cathepsin kininogenase activity is impaired
suggesting that H-kininogen is a substrate for cathepsin B under
pathophysiological conditions (Barros et al., 2004a).
GLYCOSAMINOGLYCANS AND
INFLAMMATION
Heparan sulfate (HS) polysaccharide chains are ubiquitous
GAGs in animal cells (Dietrich et al., 1983). These classes of
molecules are heteropolysaccharides composed of repeating units
of disaccharides, a uronic acid residue, either D-glucuronic
acid or L-iduronic acid, and D-glucosamine with N- and 6-
O-sulfates and N-acetyl substitutions (Dietrich et al., 1998).
HS occurs at the cell surface and in the extracellular matrix
(ECM) as proteoglycans (PGs). Most of the cellular HS derives
from the syndecans and glypicans PGs. The syndecan family
is associated with the cell membranes via transmembrane core
proteins (Yanagishita and Hascall, 1992; Elenius and Jalkanen,
1994), and the glypican family is anchored by glycosilyl
phosphatidylinositol-anchor core proteins (David, 1993). In
addition, heparan sulfate proteoglycans (HSPGs) are present in
basement membranes as the perlecan family (Iozzo et al., 1994).
HSPGs regulate a wide variety of biological process including
hemostasis, inflammation, angiogenesis, growth factors, and cell
adhesion, and play a major role in the ECM (Conrad, 1998). The
interactions occurring in the ECM with HSPG have shown the
direct regulation of the fibroblast growth factors (FGFs) diffusion
that can determine the shape of growth concentration gradients
in development, as well as the storage and release of FGFs in
tissue homeostasis. The growth factor/morphogen-type signals
generated by FGFs require the assembly of the ternary complex
of FGF ligand, FGF receptor (FGFR) and HS, which engages both
the ligand and receptor, acting as a co-receptor (Li et al., 2016).
The heparin-related GAG chains of the HSPGs are involved in
the inflammatory process through binding and modification of
the activity of several molecules (Götte, 2003).
Heparin and HSPGs can alter the proteolytic activity of
various serine proteases of the coagulation cascade as well as
their natural inhibitors, the serpins (Ermolieff et al., 1994; Gettins
et al., 1996; Fath et al., 1998). HSPGs can also control the activity
of several serine proteases directly involved in the inflammatory
response. Data from the literature show that ectodomains
of syndecan-1 and syndecan-4 present in acute inflammatory
fluid are able to regulate the proteolytic activity of cathepsin
G and elastase. The enzymatic degradation of polysaccharide
chains of HS in HSPGs promotes strong inactivation of
elastase and cathepsin G serine proteinases present in the
inflammatory fluid (Kainulainen et al., 1998). The syndecan-1
ectodomain protects the inhibition of cathepsin G by the natural
inhibitors, the serpin α1-antichymotrypsin and squamous cell
carcinoma antigen-2 and protects the inhibition of elastase by
α1-antichymotrypsin.
At the neutrophil surface HSPGs bind human neutrophil
elastase (HNE) and preserve its activity by protecting it from
inhibition by α1-antitrypsin and secretory leukocyte peptidase
inhibitor and focus the activity of HNE to the pericellular
environment (Campbell and Owen, 2007). Syndecan knockout
mice show deficits in tissue repair (Bishop et al., 2007). In
mast cells, intracellular heparin PG serglycin compartmentalizes
various proteolytic enzymes, among them chymase and tryptase
proteases (Pejler et al., 2007). The major intracellular PG of
hematopoietic cells is serglycin PG which has been related to
sorting and packing of granule HNE (Niemann et al., 2007).
HNE can also regulate tissue inhibitor of metalloproteases-
1 (TIMP-1) and metalloproteinase-9 (MMP-9) activities. In the
pro-MMP-9/TIMP-1 complex, HNE preferentially inactivates
TIMP-1 and renders pro-MMP-9 activity through MMP-3 (Itoh
and Nagase, 1995). TIMP-1, as an inhibitor of MMP-2 andMMP-
9, is tightly correlated to the maintenance of the ECM structure
(Murphy and Nagase, 2008). An MMP-9/TIMP-1 imbalance,
caused by the proteolytic activity of HNE, has an important
pathophysiological role in the sputum of patients with cystic
fibrosis (Jackson et al., 2010), intracranial hemorrhage (Alvarez-
Sabín et al., 2004), abdominal aortic aneurysm (Wiernicki et al.,
2010) and bone resorption (Bord et al., 1997).
Heparin increases eight-fold the initial rate of pro-MMP-
9 autolytic activation (Crabbe et al., 1993). Interestingly, the
major clinical complication of heparin anticoagulant therapy is
hemorrhage (Zidane et al., 2000) and osteoporosis by increasing
bone resorption (Rajgopal et al., 2008) as a side effect. Heparin
accelerates the rate of hydrolysis of TIMP-1 by HNE and the
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most important adverse effects of heparin therapy are related to
excessive activation of MMP-9 (Nunes et al., 2011).
Human neutrophil proteases can release Met-Lys-BK and
BK from low-(L) and H-kininogens (Stuardo et al., 2004). The
cooperative action of mast cell tryptase and HNE can release BK
from H-kininogen and L-kininogen, with efficiency not much
lower than that of KAL. Interestingly, the release of BK from
oxidized kininogen substrate by the tryptase/elastase mixture was
not altered (Kozik et al., 1998). Therefore, the plasma level of
BK is higher in wild-type C57BL/6 mice than in elastase-deficient
mice (Sahoo et al., 2014). It is important to note that both tryptase
(Hallgren et al., 2005; Pejler et al., 2007) and neutrophil elastase
proteases (Campbell and Owen, 2007; Niemann et al., 2007) have
their proteolytic activity controlled by heparin and HSPGs.
HEPARAN SULFATE PROTEOGLYCANS
AND THE PLASMA KALLIKREIN-KININ
SYSTEM
In the early 2000s, not only HS but also chondroitin sulfate
(CS) GAGs were indicated as putative receptors that accumulate
H-kininogen on the cell surface of HUVECs and other cells
in a zinc-dependent manner, along with H-kininogen binding
proteins, the integrin receptor Mac-1/αMβ2, p33/gC1qR, uPAR,
CK1, thrombospondin-1 and glycoprotein-Ib (Renné et al., 2000;
Renné and Müller-Esterl, 2001; Fernando et al., 2003).
Previous studies concerning KKS purified protein assembly
on the ECM of different endothelial cell lines, from rabbit aorta
endothelial cells (RAECs) and ECV304 cells, suggest that not
only the cell membranes but also the ECM produced by these
cells assemble H-kininogen/PK as a complex and form KAL
that activates pro-urokinase, which in turn activates plasminogen
(Motta et al., 2001).
On the RAEC surface or ECM, GAGs also influence this
process because in the presence of Zn2+ heparin abolishes H-
kininogen binding which is reduced by HS and other GAGs;
in contrast, only heparin reduces H-kininogen binding to the
ECV304 surface or ECM. Heparin does not modify PK binding
and activation in the presence of H-kininogen assembled to the
cell surface or ECM. In the fluid phase, heparin in the presence of
Zn2+augments the BK release from H-kininogen after hydrolysis
by KAL. GAGs that accumulate in inflammatory fluids or are
used as a therapeutic drug (e.g., heparin) could act as pro- or anti-
inflammatory mediators depending on different factors within
the cell environment (Gozzo et al., 2011).
The current research group is the first to show that the
interaction of H-kininogen and PK on the cell surface mediated
by HSPGs results in endocytosis (Melo et al., 2009; Veronez
et al., 2014; Damasceno et al., 2015; Figure 1). H-kininogen
interacts with cellular sites in either RAECs or epithelial CHO
cells, wild type CHO-K1 cells and CHO-745 cells, mutant cells
deficient in xylosyltransferase and as consequence is involved
in GAG biosynthesis. The HS chain of HSPG is involved in H-
kininogen binding to RAECs and CHO-K1 cells. The interaction
parameters of H-kininogen with RAECs and CHO cells are
strongly dependent on temperature and the interaction between
H-kininogen and cells was not totally reversible at 37◦C; the
interaction with CHO cells is related to vital processes also
influenced by ATP synthesis; the H-kininogen interaction in
CHO cells is independent of cycloheximide, indicating that new
protein synthesis does not influence H-kininogen binding. GAGs
are not the main cellular receptors; however, GAGs modulate the
cellular receptors of H-kininogen in CHO cells (Melo et al., 2009).
In CHO-K1 cells, after H-kininogen interacts with HS at
the cell surface, it is internalized by endocytosis followed by
a fusion step within an acidic endosomal compartment. The
endocytosis process of H-kininogenin CHO-K1 cells is disrupted
by pretreatment of the cells using chloroquine, an alkalinizing
agent of acid endosomes; cholesterol depletion by methyl-β-
cyclodextrin also inhibits endocytosis; the endocytosis of H-
kininogen is independent of transferrin endocytosis, strongly
indicating that the endocytosis of H-kininogen is not dependent
on clathrin. The membrane lipid raft domains/caveolae mediate
the endocytotic process of H-kininogen, as the colocalization of
H-kininogen with caveolin-1 has been demonstrated (Melo et al.,
2009; Damasceno et al., 2015).
In contrast, CHO-745 cells, which are almost completely
devoid of GAGs, do not take up intact H-kininogen; the
inhibition of GAG sulfation blocks the endocytosis process, and
the integrity of H-kininogen is very important for internalization
since BK-free H-kininogen does not become internalized
(Veronez et al., 2014; Damasceno et al., 2015).
The cysteine proteases play a role in H-kininogen processing
on the cell surface and in acidic endosomal vesicles. At neutral
pH and after H-kininogen assembly on the cell surface, kinin
generation was much higher in CHO-K1 cells, and tumorigenic
cells, when compared with RAECs, as expected, as either serine
or cysteine proteases are involved in kinin release. In CHO-745
cells, only serine protease activity is detected consistently with the
regulation of cysteine proteases by GAGs/PGs in H-kininogen
processing and kinin release (Melo et al., 2009; Damasceno
et al., 2015). The lysate fraction of CHO-K1 cells possesses
kininogenase activity at pH7.4 but the total cleavage of intact H-
kininogen is more effective at pH 5.5 after a 4 h incubation. In
crude lysates, the hydrolysis patterns are quite similar suggesting
a kininogenase activity at a pH optimum of 5.5 that can still work
at pH 7.4, albeit more slowly. The antipain-Sepharose affinity
chromatography of the CHO-K1 cell lysate fraction successfully
separates different kininogenases (Damasceno et al., 2015).
Other groups have shown that H-kininogen binding toHS and
CS efficiently interferes with BK release by KAL, in plasma and
on endothelial surfaces (Renné et al., 2005), and two enzymes
purified from HUVECs are described as PK activators on cells,
the heat shock protein 90 and prolylcarboxypeptidase (Bryant
and Shariat-Madar, 2009).
PK interacts directly with the endothelial cell surface
independent of the presence of H-kininogen (Motta et al., 1998).
The PK interaction with CHO and ECV304 cells shows that
although the process is temperature-dependent, it also depends
on the GAG composition of the cell type. HSPGs direct PK to
acidic endosomal vesicles and the endocytosis process of PK/KAL
depends on GAGs, but not those bound to H-kininogen. PK
interaction with GAGs does not disturb its cleavage/activation;
therefore, H-kininogen bound to GAGs may modulate PK as
a control mechanism of KAL activity (Veronez et al., 2014).
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FIGURE 1 | Modulation of Plasma Kallikrein-Kinin System: the Role of Heparan Sulfate Proteoglycans. H-kininogen (HK) or plasma prekallikrein (PK) alone, or as a
complex (HK/PK), are associated with the cell surface. The heparan sulfate proteoglycans (HSPG) in the membrane microdomains can function as ligands for these
molecules, promoting caveolae-mediated endocytosis. Once present in the primary endosome, these ligands can escape to the cytoplasm or be processed after the
fusion between endosomes and lysosomes. Furthermore, these molecules may undergo proteolysis on the cell surface by serine or cysteine proteases. The HSPGs
can be recycled to the cell surface.
Either cathepsin B or cathepsin L, which are lysosomal cysteine
proteases, might hydrolyze PK or KAL (Barros et al., 2004b).
Figure 1 illustrates the concept that after blood vessel
injury, H-kininogen and PK or KAL can interact and
bind to the HSPGs of non-endothelial cells. On lipid raft
domains/caveolae or endosomes, HSPGsmediate the endocytosis
of intact H-kininogen, which can be processed by different
classes of proteases. The cleavage produces H-kininogen
fragments that may play roles as cystatins, effectors of innate
immunity, inflammation, angiogenesis, and coagulation. The
KAL proteolytic balance of H-kininogen/BK free H-kininogen
forms is controlled by GAGs, which may promote this control
in two different ways: controlling the proteolytic activity of
the ternary complex GAG/H-kininogen/KAL or the cellular
compartmentalization of KKS proteins via endocytosis.
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